Edward Smolyansky Provides Update on Consent Solicitation to Restore Board Accountability at Lifeway Foods (NASDAQ: LWAY) and End Shareholder Disenfranchisement
Edward and Ludmila Smolyansky, controlling approximately 26% of Lifeway Foods (NASDAQ: LWAY), have provided an update on their consent solicitation process initiated on July 2, 2025. The shareholders are challenging the current board's actions, particularly criticizing the rejection of Danone's offer which represented a 72% premium over the 3-month volume weighted average price.
The Smolyanskys highlight several controversial board actions, including the adoption of a poison pill, delayed 2025 annual meeting, and a $8.5 million compensation package for CEO Julie Smolyansky. They're seeking shareholder support by August 1, 2025, to replace the incumbent directors and enable an independent evaluation of Danone's offer.
Edward e Ludmila Smolyansky, che controllano circa il 26% di Lifeway Foods (NASDAQ: LWAY), hanno fornito un aggiornamento sul processo di raccolta di consensi avviato il 2 luglio 2025. Gli azionisti contestano le azioni dell'attuale consiglio di amministrazione, criticando in particolare il rifiuto dell'offerta di Danone, che rappresentava un premio del 72% rispetto al prezzo medio ponderato per il volume degli ultimi 3 mesi.
I Smolyansky sottolineano diverse azioni controverse del consiglio, tra cui l'adozione di una poison pill, il rinvio dell'assemblea annuale del 2025 e un pacchetto di compensi da 8,5 milioni di dollari per la CEO Julie Smolyansky. Chiedono il sostegno degli azionisti entro il 1° agosto 2025 per sostituire i direttori attuali e permettere una valutazione indipendente dell'offerta di Danone.
Edward y Ludmila Smolyansky, que controlan aproximadamente el 26% de Lifeway Foods (NASDAQ: LWAY), han proporcionado una actualización sobre su proceso de solicitud de consentimiento iniciado el 2 de julio de 2025. Los accionistas están cuestionando las acciones del actual consejo, criticando especialmente el rechazo de la oferta de Danone, que representaba una prima del 72% sobre el precio promedio ponderado por volumen de los últimos 3 meses.
Los Smolyansky destacan varias acciones controvertidas del consejo, incluyendo la adopción de una poison pill, el retraso de la junta anual de 2025 y un paquete de compensación de 8,5 millones de dólares para la CEO Julie Smolyansky. Buscan el apoyo de los accionistas antes del 1 de agosto de 2025 para reemplazar a los directores actuales y permitir una evaluación independiente de la oferta de Danone.
에드워드와 루드밀� 스몰리얀스키� Lifeway Foods (NASDAQ: LWAY)� � 26%� 보유하고 있으�, 2025� 7� 2� 시작� 동의 요청 절차� 대� 업데이트� 제공했습니다. 주주들은 현재 이사회의 행동� 이의� 제기하며, 특히 3개월 거래� 가� 평균 가� 대� 72% 프리미엄� 제시� 다논� 제안 거부� 비판하고 있습니다.
스몰리얀스키 부부� 독약 조항(poison pill) 채택, 2025� 연례 총회 연기, CEO 줄리 스몰리얀스키� 대� 850� 달러 보상 패키지 � 여러 논란� 되 이사� 조치� 강조했습니다. 그들은 2025� 8� 1일까지 주주들의 지지� 얻어 � 이사들을 교체하고 다논 제안� 대� 독립적인 평가� 가능하� 하려 하고 있습니다.
Edward et Ludmila Smolyansky, détenant environ 26% de Lifeway Foods (NASDAQ : LWAY), ont fourni une mise à jour sur leur processus de sollicitation de consentement lancé le 2 juillet 2025. Les actionnaires contestent les actions du conseil d'administration actuel, critiquant notamment le rejet de l'offre de Danone, qui représentait une prime de 72% par rapport au prix moyen pondéré par le volume sur 3 mois.
Les Smolyansky soulignent plusieurs actions controversées du conseil, dont l'adoption d'une poison pill, le report de l'assemblée générale annuelle 2025, et un package de rémunération de 8,5 millions de dollars pour la PDG Julie Smolyansky. Ils recherchent le soutien des actionnaires avant le 1er août 2025 pour remplacer les administrateurs en place et permettre une évaluation indépendante de l'offre de Danone.
Edward und Ludmila Smolyansky, die etwa 26% von Lifeway Foods (NASDAQ: LWAY) kontrollieren, haben ein Update zu ihrem am 2. Juli 2025 gestarteten Zustimmungsersuchen gegeben. Die Aktionäre stellen die Maßnahmen des derzeitigen Vorstands infrage und kritisieren insbesondere die Ablehnung des Angebots von Danone, das einen 72%igen Aufschlag gegenüber dem volumengewichteten Durchschnittspreis der letzten 3 Monate darstellte.
Die Smolyanskys heben mehrere umstrittene Vorstandsentscheidungen hervor, darunter die Einführung einer Giftpille, die Verschiebung der Hauptversammlung 2025 und ein 8,5 Millionen Dollar Vergütungspaket für CEO Julie Smolyansky. Sie suchen die Unterstützung der Aktionäre bis zum 1. August 2025, um die amtierenden Direktoren zu ersetzen und eine unabhängige Bewertung des Danone-Angebots zu ermöglichen.
- Potential acquisition offer from Danone at 72% premium over 3-month VWAP
- Significant shareholder support including current and former employees
- Large shareholders (26% ownership) actively working to maximize shareholder value
- Board awarded CEO $8.5M compensation package representing 94% of 2024 Net Income
- Lead Independent Director sold 99.99% of his shares despite claiming Danone's offer undervalued the company
- Board adopted defensive measures including poison pill and delayed annual meeting
- Potential litigation risks regarding disputed 1999 shareholder agreement with Danone
Insights
Smolyansky family's battle to oust Lifeway's board highlights serious corporate governance issues amid rejected Danone acquisition.
This shareholder activism campaign represents a significant conflict over corporate control at Lifeway Foods. Edward and Ludmila Smolyansky, controlling 26% of voting shares, are soliciting shareholder consents to replace the entire board by August 1st, alleging serious corporate governance failures.
The core allegations against the current board, led by CEO/Chair Julie Smolyansky, are particularly concerning from a governance perspective:
- Rejection of Danone's acquisition offer representing a
72% premium over recent trading prices without proper independent evaluation - Implementation of anti-takeover defenses including a poison pill
- Delaying the 2025 annual shareholder meeting, typically held in June
- Questionable compensation decisions, including an equity grant and retention bonus to Julie Smolyansky totaling
$8.5 million (reportedly94% of 2024 net income) - Lead Independent Director Jason Scher's sale of nearly all personal shares while maintaining the company was undervalued
This conflict illustrates classic agency problems in corporate governance - when management's interests potentially diverge from shareholders'. The delay of annual meetings and adoption of defensive measures suggest entrenchment concerns, while the compensation decisions raise questions about board independence and proper oversight.
The Smolyanskys' consent solicitation represents a critical inflection point for Lifeway, as it will determine whether shareholders support the current board's vision or prefer new leadership that would likely reconsider Danone's acquisition offer.
Smolyansky shareholders contest board's rejection of Danone's premium offer, highlighting key M&A governance failures.
This situation presents a textbook example of contested M&A dynamics where management's rejection of an acquisition offer has triggered significant shareholder backlash. The facts present several critical M&A governance concerns:
Danone's rejected offer reportedly represented a
The resistance to Danone's approach appears particularly questionable given the company's assertion that a 1999 shareholder agreement with Danone was suddenly invalid after 25 years. Rather than engaging constructively with a potential acquirer offering significant value, the board allegedly threatened litigation.
The timing of defensive measures is particularly telling. The board's adoption of a poison pill, delay of the annual meeting, and executive compensation arrangements collectively suggest potential entrenchment rather than shareholder value maximization. The
The Lead Independent Director's decision to sell nearly all personal shares at
This proxy contest will likely determine whether shareholders receive the premium valuation offered by Danone or continue with current management.
Voting is Still Open: Shareholders Requested to Submit Consent by August1 to Make their Voices Heard
We launched this campaign out of our sincere belief that the Lifeway Board, led by its CEOand Chair Julie Smolyansky, has been both flagrant and unrelenting in its efforts to disenfranchise shareholders. We believe that Lifeway's rejection of Danone's offer, which represented a
To make matters worse, instead of safeguarding shareholder interests, the Lifeway Board appears to be focused on making sure it is not held accountable. In this pursuit, the Board has deployed the most egregious set of defense maneuvers to undermine the fundamental rights of shareholders. Based on Lifeway's public disclosures to date, those maneuvers include:
- Refusing to establish an independent special committee to evaluateDanone's offers;
- Adopting a poison pill;
- Delaying the 2025 annual meeting of shareholders, typically held in June, in an apparent attempt to delay shareholders' right to hold the incumbent directors accountable;
- Alleging that a 1999 shareholder agreement withDanone was somehow invalid 25 years later, and threatening litigation instead of negotiating with Danone in the best interest of shareholders;
- Engaging in unprecedented self-enrichment with an equity grant and retention bonus awarded by the Board to the CEO/Chair JulieSmolyansky totaling
, equating to$8.5 million 94% of Lifeway's 2024 Net Income; and - Attempting to obstruct the written consent process, as an alternative to the indefinitely delayed director election, by denying our June 17, 2025 request to fix a record date.
Amid these reprehensible acts, shareholders should be deeply concerned as to why Jason Scher, Lead Independent Director and Chair of the Audit and Corporate Governance Committee, sold all but one of his 24,567 shares at an average share price of
It has been encouraging to hear directly from shareholders, including current and former employees, who have voiced their support and voted in favor of our proposals. It reinforces our belief that this change is not only necessary, but widely supported.
We believe that the best available alternative for shareholders to hold the Board accountable is participation in the consent solicitation process. We urge investors to protect their investment and open a path for an independent evaluation of Danone's value-maximizing offer by granting us their consent to replace the incumbent directors. It is time to hold the Board accountable for its shameful record of shareholder disenfranchisement.
How to Submit Your Consent
If you have not already submitted your consent, we urge you to do so as soon as possible to support this important effort.
- Beneficial Owners (also known as "Street Name" holders): If you hold your shares through a brokerage firm, bank, or other nominee, you should have received consent materials from your custodian, along with instructions on how to vote. Please follow those instructions to submit your consent in favor of theSmolyansky proposals.
- Registered Shareholders (those who hold shares directly with the transfer agent): Please sign, date, and return the consent card in the envelope provided.
For more information and to contact the shareholder group, visit and.
Important Information
This communication is not a request for a proxy to vote on, or shareholder consent with respect to, any matter. Any written solicitation of a proxy or shareholder consent by Mr. Smolyansky or Mrs. Smolyansky will be made through a definitive proxy statement or definitive consent statement, including the definitive consent statement filed by them with the SEC on July 2, 2025(the "Consent Statement"). Lifeway shareholders are urged to read the Consent Statement, including any amendments or supplements thereto, and any other soliciting materials, when they become available as they will contain important information. Shareholders may obtain, free of charge, copies of the Consent Statement and other relevant documents at sec.gov.
Participants in the Solicitation
Mr. Smolyansky and Mrs. Smolyansky filed the Consent Statement with the SEC on July 2, 2025, which relates to, among other matters, their intent to seek shareholder consents to remove Lifeway's current board of directors and elect each of Ludmila Smolyansky, Edward Smolyansky, Richard Beleutz, Cindy Curry, Michael Leydervuder, George Sent, and Robert Whalen (each, a "Nominee") as directors of Lifeway. In addition, Mr. Smolyansky filed a preliminary proxy statement with the SEC on April 16, 2025, relating to his intent to nominate each Nominee for election as directors of Lifeway at its 2025 annual meeting of shareholders. Each Nominee may be deemed to have an interest in any solicitation of written consents or proxies by Mr. Smolyansky and Mrs. Smolyansky, as applicable.
The participants (the "Participants") in any solicitation of shareholder consents or proxies by Mr. Smolyansky or Mrs. Smolyansky may be deemed to be Mr. Smolyansky, Mrs. Smolyansky and each of the other Nominees. Lifeway shareholders can obtain information regarding the Participants and their direct and indirect interests, by security holdings or otherwise, in Appendix B to the Consent Statement, which information is incorporated herein by reference.
View original content:
SOURCE Edward and Ludmila Smolyansky